Experimental drug AB-218 tested in brain tumor patients

NCT ID NCT05577416

Completed Disease control Sponsor: Melbourne Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called AB-218 (safusidenib) in 14 adults with a specific type of slow-growing brain tumor (IDH1 mutated low grade glioma) who were already scheduled for surgery. The goal was to see if it's possible to measure how much drug gets into the tumor and to check for safety. Participants took the drug for 28 days before surgery, and some continued afterward to monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Safusidenib Erbumine (AB-218)
What this could lead to: If successful, this could help determine whether AB-218 reaches brain tumors effectively and is safe, potentially leading to a new treatment option for IDH1 mutated low grade glioma.
What could go wrong: This is an early-phase trial with only 14 participants, so results may not apply to all patients. The drug may not show enough benefit or could cause side effects, and further larger studies are needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) glioma low grade glioma oligodendroglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Locations

Royal Melbourne Hospital

Melbourne, Victoria, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.